CV DEATH HAS A NEW OPPONENT
CV DEATH HAS A NEW OPPONENT

Empagliflozin (JARDIANCE) in low eGFR HFrEF patients

Document ID: PC-PH-103491

06/12/2022

Author: Boehringer Ingelheim

Related content

 
PC-PH-103491
Production date: December 2022